Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

Marks & Spencer CEO Stuart Machin insisted the high street retailer – which reported a 1% year-on-year rise in clothing and ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...